US Stock Market Move | BEIGENE (ONC.US) rose more than 2%, institutions say that Chinese innovative drugs going abroad are not affected by tariffs.

On Monday, BEIGENE (ONC.US) rose more than 2% to $251.10. CICC International believes that the enthusiasm of multinational companies (MNC) in purchasing innovative drug assets in mainland China remains strong and will continue to be an important driver for the outflow of China's mainland innovative drugs. Influenced by political factors such as tariffs from GEO Group Inc, as well as the gradual promotion of centralized procurement, the development of domestic substitutes will accelerate, benefiting domestic equipment industry leaders. In addition, the main way for innovative drugs in mainland China to go overseas is through the authorized outflow model, which does not involve actual product exports, so it is not affected by tariffs.